Clinical Scorecard: Impact of Tegileridine Pretreatment on Cough Induced by Fentanyl During Induction of General Anesthesia: A Randomized Controlled Study
At a Glance
Category
Detail
Condition
Fentanyl-induced cough (FIC)
Key Mechanisms
Tegileridine is a G-protein-biased μ-opioid receptor agonist that may modulate opioid-induced cough.
Target Population
Adults aged 18–65 years scheduled for elective surgery under general anesthesia.
Care Setting
Department of Anesthesiology
Key Highlights
Tegileridine reduced FIC incidence from 28.7% to 11.1%.
Relative risk of FIC decreased by 61.3% with tegileridine pretreatment.
Cough severity was significantly lower in the tegileridine group.
No significant hemodynamic changes or immediate adverse events were noted.
Guideline-Based Recommendations
Diagnosis
FIC is diagnosed based on the occurrence of cough within 2 minutes after fentanyl injection.
Management
Tegileridine 0.5 mg pretreatment is suggested to reduce FIC incidence and severity.
Monitoring & Follow-up
Monitor for cough episodes and hemodynamic stability post-fentanyl injection.
Risks
Potential for increased intracranial, intraocular, and intra-abdominal pressures due to FIC.
Patient & Prescribing Data
Adults aged 18–65 years with ASA physical status I–III.
Tegileridine may be considered for patients at risk of FIC during anesthesia induction.
Clinical Best Practices
Use tegileridine as a pretreatment to mitigate FIC during fentanyl administration.
Ensure patient eligibility based on exclusion criteria to avoid complications.
